Skye Bioscience has abandoned its plans in ophthalmology after a Phase II failure and will now focus exclusively on its obesity candidate, the cannabinoid 1 receptor (CB1) inhibitor nimacimab.
Key Takeaways
-
The withdrawal of Sanofi’s CB1 inhibitor Acomplia set back obesity drugs for a decade.
The immediate market response to the news on 10 June was not positive, with Skye’s share price falling by nearly...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?